IL6 and cervical carcinoma: This indicated an option to deprive the activated IL-6/STAT3 network against inflammation including fibroblast senescence in tumor microenvironment (Fig 6) which may be considered as a complement to increase the efficacy of the targeted therapy against HPV 16/18 in cervical cancer [46].